UNSPSC 51314367: Dextromethorphan/potassium guaiacolsulfonate/promethazine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE508. This VA Drug Class (RE508) classifies this compound as belonging to the group ANTIHISTAMINE/ANTITUSSIVE/EXPECTORANT.

UNSPSC 51314367 Dextromethorphan/potassium guaiacolsulfonate/promethazine is a Commodity code that encompasses branded and generic pharmaceutical formulations combining cough suppressants, expectorants, and antihistamines, though recent state and local solicitations show limited direct purchasing under this specific code. The source records reveal that state and local governments are instead buying naloxone products, generic multi-source pharmaceuticals through cooperative purchasing alliances, and exploring direct-to-manufacturer prescription programs—categories that sit adjacent to but do not directly align with the code's narrow therapeutic composition. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing consortiums (MMCAP administered by Minnesota Department of Administration), reflecting a mix of direct procurement by individual jurisdictions and coordinated purchasing across multiple state and local participants.

The geographic spread covers Florida and Texas with significant activity in Minnesota and participating cooperative-purchasing states including Oregon. Recent opportunities include Seminole County's IFB 60459723LAS for naloxone and drug deactivation systems with a July 26, 2023 response deadline; Texas HHS's RFI HHS0017013 for direct-to-manufacturer prescription program capabilities, posted April 3, 2026; and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 proposal deadline. The MMCAP solicitation is the most directly aligned with this code's scope, requiring manufacturers to supply identified pharmaceutical products through designated wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) with awards effective July 1, 2026, and evaluation weighted 75 percent on price competitiveness. However, the code shows no substantial recent activity specifically for the dextromethorphan-based combination named in the UNSPSC category; state and local procurement under this code tier appears minimal.